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Does Granulocyte Colony–Stimulating Factor Affect Survival
in Patients with Advanced Non-small Cell Lung Cancer?
Goulnar Kasymjanova, MD,* Harvey Kreisman, MD,*† Jose´ A. Correa, PhD,§
Esther Dajczman, RN, MScA,‡ and David Small, MDCM*†
Background: Platinum-based chemotherapy is standard treatment
for patients with advanced lung cancer. The common side effect of
this therapy is myelosuppression, for which different stimulating
factors are used. In this article, the effect of granulocyte colony–
stimulating factor (G-CSF) administration on the survival of patients
with unresectable non–small-cell lung cancer (NSCLC) was evaluated.
Methods: The charts of 127 patients, treated with carboplatin-based
chemotherapy, were reviewed for histology, stage, performance
status, weight loss, treatment regimen, toxicity, and survival. Eighty
patients were stage IIIA/IIIB NSCLC; 47 were stage IIIB (pleural
effusion) or stage IV. Eighty-one patients (63%) experienced severe
(grades 3 and 4) neutropenia. Forty-two patients received G-CSF, 37
patients for severe neutropenia (14 with febrile neutropenia) and five
patients for active infection during chemotherapy.
Results: Preliminary analyses, both unadjusted (median survival, 20
months versus 13.8 months; log-rank test, p 0.02) and adjusted for
covariates of interest (Cox regression, hazard ratio  0.62, p 
0.03) showed a significant effect of the use of G-CSF on survival,
even though the groups were balanced with respect to stage, perfor-
mance status, weight loss, and dose intensity of chemotherapy.
Patients with grades 3 and 4 neutropenia (whether they received
G-CSF or not) had a better survival outcome compared to those who
did not have neutropenia (median survival, 17.6 months versus 11.9
months, log-rank test, p  0.04). A landmark analysis showed a
marginally significant effect of G-CSF on survival (median survival,
18.6 months versus 15.1 months, log-rank test, p 0.08), even after
adjustment for covariates. The Cox regression with the use of
G-CSF defined as a binary time-varying covariate also showed
similar results (Cox regression, hazard ratio  0.67, 95% CI:
0.42–1.04, p  0.07).
Conclusion: In this study, the time bias due to the delayed admin-
istration of G-CSF contributed to the longer survival of patients
receiving G-CSF. Prospective studies are required to determine
whether G-CSF has any effect on survival in patients with advanced
NSCLC.
Key Words: Non–small-cell lung cancer, Granulocyte colony–
stimulating factor, Neutropenia, Landmark analysis.
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Platinum-based chemotherapy prolongs survival comparedto the best supportive care in patients with advanced
non–small-cell lung cancer (NSCLC).1,2 The most often used
regimens have similar efficacy, but the toxicity of these
regimens may adversely affect the patient’s quality of life
(QOL).3–6
Chemotherapy-induced neutropenia is the primary
dose-limiting and potentially life-threatening complication in
patients with NSCLC treated with chemotherapy. Grade 4
neutropenia occurs in 38% to 59% of patients and febrile
neutropenia in up to 10%.1–6 Although neutropenia may not
influence a patient’s QOL, febrile neutropenia may adversely
affect both QOL and survival. However, there is some evi-
dence that neutropenia may be a biological marker for drug
activity and eventual survival.7
The primary prophylactic administration of hematopoi-
etic growth factors such as granulocyte colony–stimulating
factor (G-CSF) increases the neutrophil count and subse-
quently decreases the duration of neutropenia, days of anti-
biotic therapy, and duration of hospitalization.8–10 Several
studies have demonstrated the feasibility of increasing the
dose intensity of chemotherapy with the use of G-CSF.
However, the survival benefit for patients with NSCLC re-
ceiving higher dose chemotherapy remains extremely limited
and patients frequently experience increased toxicity.11–17
Therefore the routine use of colony-stimulating factors
(CSFs) for primary prophylaxis in patients with advanced
NSCLC is discouraged. The American Society of Clinical
Oncology guidelines state that “in the absence of positive
effect on overall survival there is little justification for use of
CSFs outside of clinical trials.”14,15
We examined G-CSF use in our patients with NSCLC
to determine the indications for its use and effect of treatment
on chemotherapy dose intensity, toxicity, and survival.
PATIENTS AND METHODS
We reviewed the medical records of NSCLC patients
diagnosed at the Jewish General Hospital in Montreal, Que-
bec, Canada, between January 1, 1997, and December 31,
2001. The cohort included patients with histologically or
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cytologically confirmed stage III (A or B) or IV unresectable
NSCLC who were treated with carboplatin-based chemother-
apy (n  127). Characteristics abstracted from the medical
records were age, gender, histology, stage, performance sta-
tus, weight loss, severity of neutropenia, use of G-CSF, and
survival. Age was dichotomized as younger than 65 years or
65 years and older. Disease stage was categorized as IIIA/
IIIB or IIIB (with pleural effusion)/IV. Neutropenia was
categorized by grade according to the CTC criteria with the
absolute neutrophil count dichotomized as1000 109/L or
1000 109/L.17 Performance status was classified as 0/1 or
2 and higher; weight loss was dichotomized as a loss of 5
lb versus5 lb, and use of G-CSF was categorized as present
or absent.
All patients received a two-drug regimen, consisting of
carboplatin (AUC 5 or 6) and either paclitaxel (175–200
mg/m2), vinorelbine (25 mg/m2 days 1 and 8) or gemcitabine
(1000 mg/m2 days 1 and 8). Cycles were repeated every 3
(paclitaxel or gemcitabine regimens) or 4 weeks (vinorel-
bine). We recorded the use of radiotherapy and the manner in
which it was administered.
The decision to administer G-CSF was made by the
patient and his or her treating physician after discussion of
potential risks and benefits of this therapy. The current
American Society of Clinical Oncology guidelines were used
as a basis for this decision, but the final choice of treatment
was an individual one.
The chemotherapy dose intensity was defined as the
ratio of actual dose delivered to the standard protocol dose
intensity. Actual dose intensity was calculated as the amount
of drug delivered per unit time (expressed as AUC/week for
carboplatin and in milligrams per square meter per week for
the second agent). Dose intensity was then dichotomized as
85% or 85% of standard dose intensity for each agent.
The mean of the percentages for the two agents was desig-
nated as the chemotherapy dose intensity. Survival was cal-
culated from the date of diagnosis until date of death or date
of last follow-up. Toxicity was classified according to the
National Cancer Institute criteria.18,19
Statistical Methods
Comparisons between G-CSF and no G-CSF groups
were done with t tests for the continuous variables and 2
tests for the categorical variables. For survival analysis, the
Kaplan-Meier method and log-rank test were used. The Cox
proportional hazards regression model was employed to es-
timate the hazard ratios of death in the two groups. An
adjustment was made for age, gender, performance status,
stage, number of cycles, and dose intensity. Covariates in-
cluded in the primary analysis were prespecified based on the
available evidence from the other trials20 or on their effect on
survival based on a univariate regression.21 All p values were
obtained by means of two-tailed tests, and differences were
considered statistically significant when p values were0.05.
Results with p  0.1 were considered marginally significant.
To avoid the possibility of time bias due to a higher
chance of getting G-CSF with longer survival, we performed
a landmark analysis using the time point of 4 months from
diagnosis.22 Patients who died before the landmark time were
excluded from the analysis regardless whether they received
G-CSF.
All statistical analyses were carried out using SAS
software, version 9.1 (SAS Institute Inc., Cary, NC), and
SPSS software, version 12.0 (SPSS Inc., Chicago, IL).
RESULTS
Characteristics of all the 127 patients are listed in Table
1. The median age of this cohort was 61 years, and most
patients had a good performance status. One hundred nine
patients (86%) had an Eastern Cooperative Oncology Group
(ECOG) score of 0 or 1, and 18 (14%) had a performance
status of 2. Forty-nine percent of patients were found to
have adenocarcinoma. There were 47 patients (37%) with
advanced disease (IIIB pleural effusion or IV). The sites of
metastases included the lung, brain, bone, liver, and adrenal.
Three hundred ninety cycles of chemotherapy were
administered (median, two cycles), and chemotherapy-in-
duced neutropenia was the most serious hematologic toxicity
encountered. The number of patients treated in each cycle as
well as the incidence of neutropenia per cycle is shown in
Figure 1. Eighty-one patients (63%) experienced one or more
episodes of severe neutropenia. The incidence of severe
neutropenia decreased as treatment continued, being the high-
est after the first cycle of therapy. Fifty-two patients experi-
enced at least one episode of grade 4 neutropenia, and 27
patients were admitted for febrile neutropenia requiring a
median stay in hospital of 4 days (range, 2–18). Twenty-one
patients had one admission for febrile neutropenia, and six
patients had more than one admission; none had been treated
with G-CSF.
Of the 127 patients evaluated, 42 received G-CSF
support beginning 4 to 6 days after chemotherapy and con-
TABLE 1. Patient Characteristics
Characteristics No. (%)
Gender
Male 82 (64)
Female 45 (36)
Age (y)
Mean, SD 60.8, 9.2
Median, range 61, 40–78
65 74 (58)
65 53 (42)
Performance status (ECOG)
0–1 109 (86)
2 18 (14)
Histology
Adenocarcinoma 62 (49)
Squamous 42 (33)
Large cell 2 (1)
Undifferentiated 21 (17)
Stage
IIIA & IIIB 80 (63)
IIIB (Pl eff) & IV 47 (37)
ECOG, Eastern Cooperative Oncology Group; Pl eff, pleural effusion.
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tinuing until the neutrophil count exceeded 10,000  109/L.
G-CSF was administered after grade 4 neutropenia and/or
febrile neutropenia in 37 patients and as primary prophylaxis
in the presence of persisting active infection (e.g., postob-
structive pneumonia) in five others.
Patients were retrospectively classified into two groups;
those given G-CSF (n  42) and those with no G-CSF
support (no G-CSF) (n  85). Table 2 lists patient charac-
teristics in these two groups. There were no significant
differences in pretreatment characteristics.
The mean number of chemotherapy cycles adminis-
tered overall in the G-CSF group was 3.5 versus 2.7 in the no
G-CSF group (p  0.01). Twenty-nine (69%) patients in the
G-CSF group received three or more cycles of chemotherapy
versus 33 (39%) patients in the no G-CSF group (Figs. 2 and
3). The mean number of chemotherapy cycles received after
initiation of G-CSF administration in the G-CSF group was
2.0. This was not different from the mean number of treat-
ment cycles received in the no G-CSF group.
Chemotherapy dose modification (delay of next cycle
or dose reduction) was initiated due to delayed recovery of
neutrophil count or febrile neutropenia in 32% of all patients.
Thirty-nine percent of patients in the G-CSF group and 31%
in the no G-CSF group had a reduction in dose intensity of
chemotherapy (p  0.8).
Patients with G-CSF support had a better median sur-
vival than those who did not have G-CSF support (Fig. 4).
The median survival was 20 months and 13.8 months in the
G-CSF and no G-CSF groups, respectively (p  0.02).
Thirty-seven of the 81 patients (46%) with severe
neutropenia (grades 3 and 4) received G-CSF in the subse-
quent cycle of chemotherapy. Patients with grades 3 and 4
neutropenia (whether they received G-CSF or not) had a
better survival outcome compared to those who did not have
neutropenia. The median survival was 18 months in the 81
patients with neutropenia and 12 months in the 46 patients
without neutropenia (p  0.04). This survival benefit was
even more evident in the subgroup of neutropenic patients
who received G-CSF support. Those patients had a median
survival of 21 months versus 16 months in the No G-CSF
group (p  0.01) (Fig. 5).
The univariate analysis of survival (Table 3) of prog-
nostic factors confirmed that only the use of G-CSF (p 
0.02) was significantly associated with improved survival.
Performance status and disease stage were marginally signif-
icant in predicting survival. Age, gender, weight loss, dose
intensity, and number of chemotherapy cycles were not
predictive of survival.
A multivariate analysis (Table 4) of survival was used
to confirm whether G-CSF use contributed to survival benefit.
G-CSF use was the only variable that was significantly
(hazard ratio  0.62, 95% CI: 0.41–0.96, p  0.03) associ-
ated with survival and the benefit could not be explained by
an increased dose intensity of chemotherapy (p  0.89)
and/or increased number of chemotherapy cycles (p  0.71).
Although most patients receiving G-CSF were treated after
the first chemotherapy cycle, 29% of patients had this treat-
ment instituted after the second or subsequent cycles of
chemotherapy.
FIGURE 1. Number of patients at each cycle
(solid columns) and number of grades 3 and 4
neutropenia episodes with each cycle (open
columns).
TABLE 2. Group Characteristics
Characteristics G-CSF (n  42) No G-CSF (n  85) p
Age (y)
Mean, SD 61.1, 9.1 60.6, 9.3 0.79
Median, range 62, 41–74 61, 40–78
65 24 (57%) 50 (59%) 0.86
65 18 (43%) 35 (41%)
Gender
Male 27 (64%) 55 (65%) 0.96
Female 15 (36%) 30 (35%)
Stage
IIIA/IIIB 27 (64%) 53 (62%) 0.83
IIIB (Pl eff)/IV 15 (36%) 32 (38%)
ECOG
0–1 38 (90%) 71 (84%) 0.29
2 4 (10%) 14 (16%)
Pl eff, pleural effusion; ECOG, Eastern Cooperative Oncology Group.
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To reduce the potential bias that arises from the fact
that some patients died too early to receive G-CSF, we
performed a landmark analysis. The landmark time was
designated to be 4 months from diagnosis. Seven patients
were excluded from the analysis because they died before the
landmark time (none had received G-CSF). Of the remaining
120, six patients from the G-CSF group were reclassified to
the no G-CSF group because they had started on G-CSF after
the landmark point. Survival of the 84 patients who either had
not been treated with G-CSF at all or had received it after the
landmark time was then compared to survival of 36 patients
who have received G-CSF prior to the landmark time (Fig. 6).
In both the unadjusted analysis (p  0.08) and the Cox
regression adjusted for covariates, we found a marginally
significant effect of G-CSF use on survival (hazard ratio 
0.67, 95% CI: 0.42–1.03, p  0.07).
FIGURE 3. Number of cycles received by
each patient in granulocyte colony–stimulat-
ing factor (G-CSF) group. The mean num-
ber of cycles was 3.5.
FIGURE 2. Number of cycles received by
each patient in the no granulocyte colony–
stimulating factor (G-CSF) group. The mean
number of cycles was 2.7.
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The survival benefit in neutropenic patients was no
longer significant after introducing the landmark point of 4
months (p  0.24) (Fig. 7).
A Cox regression with a time-dependent covariate to
express whether a patient at any time had received G-CSF
indicated a similar result as the landmark analysis (hazard
ratio  0.69, 95% CI: 0.45–1.06, p  0.09).
DISCUSSION
This retrospective study demonstrated that the use of
G-CSF in patients with NSCLC receiving carboplatin-based
chemotherapy may be associated with significant prolonga-
tion of survival. However, the initial significant association,
in both the univariate and the multivariate analyses between
G-CSF use and survival is biased because patients who died
early did not get a chance to receive G-CSF. In this study,
G-CSF was rarely administered as initial treatment.
In addition, the increased survival in neutropenic pa-
tients may partially be explained by length bias, as patients
FIGURE 4. Kaplan-Meier survival curves for granulocyte col-
ony–stimulating factor (G-CSF) and no G-CSF patients.
FIGURE 5. Kaplan-Meier survival curves of neutropenic pa-
tients with or without granulocyte colony–stimulating factor
(G-CSF) support.
TABLE 3. Univariate Analysis of Survival
Variable p
Age 0.24
Gender 0.21
PS 0.05
Weight loss 0.20
Stage 0.05
No. of cycles 0.15
DI 0.60
G-CSF use 0.02
PS, performance status; DI, dose intensity; G-CSF, granulocyte colony–stimulating
factor.
TABLE 4. Multivariate Analysis of Survival
Prognostic factor Hazard ratio (mortality) 95% CI p
G-CSF 0.62 0.41–0.96 0.03
Age 1.19 0.79–1.81 0.40
Gender 1.25 0.82–1.90 0.31
Stage 1.39 0.93–2.07 0.10
PS 1.59 0.90–2.80 0.11
Weight loss 1.12 0.73–1.72 0.61
No. of cycles 0.93 0.61–1.40 0.71
DI 1.04 0.69–1.57 0.84
CI, confidence interval; G-CSF, granulocyte colony–stimulating factor; PS, perfor-
mance status; DI, dose intensity.
FIGURE 6. Kaplan-Meier survival curves for granulocyte col-
ony–stimulating factor (G-CSF) and no G-CSF patients using
landmark point of 4 months.
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who lived longer probably received more chemotherapy and
had a greater likelihood of developing neutropenia (Figs. 5
and 7).
The association between G-CSF use and survival was
marginally significant after evaluation using either a land-
mark analysis or a Cox regression with a time-dependent
covariate, the two approaches used to reduce the bias.
Several studies have evaluated the efficacy of the CSFs
in reducing the severity and the risk of infection associated
with dose-intense chemotherapy23–28. These trials demon-
strated that increased dose intensity is possible when using
G-CSF as an adjunct. However, any benefit in terms of
response rate or survival for patients receiving higher dose
therapy has not been proven.27 Other studies have shown that
CSFs decrease the overall incidence of neutropenic events but
have had a disappointingly small impact on disease-free and
overall survival in other solid tumors.26–32 A recent meta-
analysis showed a trend toward reduced mortality during
chemotherapy with CSF support, but did not comment on
overall survival.10
The lack of association between number of cycles and
survival in the multivariate analysis is consistent with the
report of Smith et al.,33 indicating that there was no clinical
benefit to continuing chemotherapy beyond three cycles in
patients with NSCLC. A phase III study by Socinski et al.34
also failed to show an overall clinical benefit of continuing
chemotherapy beyond four cycles.
The association between severe neutropenia and in-
creased survival is a provocative one. The fact that severe
neutropenia is better than no neutropenia in predicting sur-
vival was demonstrated by Di Maio et al.7 However, land-
mark analysis of our cohort failed to show the difference in
survival. The initial finding might suggest that neutropenia
could be a surrogate marker for efficacy of chemotherapy and
that those patients with severe neutropenia (with or without
G-CSF subsequently) survived longer because of a greater
biological effect of chemotherapy. Cancer biology, however,
is a more complex process, and it is overly simplistic to view
neutropenia as a surrogate for chemotherapy efficacy.
There is a broad interindividual variation in drug dis-
position, based on age, sex, and renal and hepatic function.35
In addition single-peptide polymorphisms may produce wide
variations in drug toxicity as well as efficacy by altering the
transport of drugs into the cell, its metabolism, DNA repair,
and other processes.36,37 Carboplatin, gemcitabine, paclitaxel,
and vinorelbine are all subject to such a variation in ef-
fect.37–39
Colony-stimulating factors may have biological effects
that are independent of their role in diminishing the severity
of neutropenia.40 This could potentially have affected the
survival benefit in those patients receiving G-CSF. In this
study, the effect of neutropenia on survival was even greater
in the group receiving G-CSF (Fig. 5). This suggests a
possible independent role for G-CSF.
Clinical evaluation and reassessment of prognostic fac-
tors may have influenced the decision to use G-CSF rather
than reduction or cessation of chemotherapy. Other prognos-
tic factors not included in the model may also have influenced
the decision to give G-CSF.
In conclusion, this study suggests that patients with
NSCLC receiving chemotherapy with G-CSF support may
have better survival than those without G-CSF support. Any
study should, however, take into account the possibility of
bias from that fact that longer survival may influence the
chance of getting G-CSF.
The role of a pharmacogenomically mediated effect,
with greater toxicity and efficacy, cannot be ruled out. In
addition, clinical judgment in selecting patients for more
treatment including G-CSF may have been a factor in this
retrospective analysis. Validation of these results would re-
quire a randomized, controlled trial (Table 5.
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